Eye care compositions for improving ocular microcirculation and use thereof

Abstract

The application belongs to the technical field of cosmetics, and particularly relates to an eye care composition for improving microcirculation around eyes and application thereof. The composition is composed of the following components in mass parts: 0.05-3 Gastrodia elata extract solution, 0.001-0.5 hydroxyl asiaticoside and 0.02-2 Miechunka 50. An eye care product for improving microcirculation around eyes is also provided, in which the mass content of the Gastrodia elata extract solution is 0.05%-3%, the mass content of the hydroxyl asiaticoside is 0.001%-0.5%, the mass content of the Miechunka 50 is 0.02%-2%, and other components are matrix adjuvants. Compared with the prior art, the composition provided by the application has better comprehensive efficacy than single components, exhibits a significant synergistic effect, can quickly improve the skin color state around eyes, has a certain effect persistence, and can be used for relieving the dark circles under eyes, eye bags and eye fatigue state around eyes caused by poor microcirculation, oxidative stress and inflammatory response.

Description

Technical Field

[0001] This invention belongs to the field of cosmetic technology, and in particular relates to an eye care composition for improving microcirculation around the eyes and its application. Background Technology

[0002] The skin around the eyes has a thin stratum corneum, little subcutaneous fat, and a rich distribution of capillaries, making it susceptible to damage from factors such as staying up late, fatigue, mental stress, aging, and prolonged use of electronic screens. This can lead to weakened local microcirculation and obstructed blood and lymphatic return, resulting in problems such as dark circles, puffiness, dullness, and fine lines. Slowed blood circulation can cause the deposition of hemoglobin and hemosiderin, causing bluish-purple dark circles. At the same time, local inflammation and oxidative damage can further weaken the stability of microvessels, exacerbating dark circles and swelling around the eyes.

[0003] To address the aforementioned issues, existing technologies have proposed several improvement solutions. Patent CN111759786A discloses an eye cream for reducing dark circles and eye bags, which improves periocular vascular circulation through extracts of Salvia miltiorrhiza and Gastrodia elata. However, its mechanism of action focuses solely on blood circulation, lacking synergistic regulation of accompanying oxidative stress, micro-inflammation, and capillary stability. Patent CN120585713A discloses a cosmetic composition for lightening dark circles, containing ingredients such as caffeine and glucosyl hesperidin, which can improve microcirculation and reduce pigmentation. However, its long-term effects have not been fully verified, and its comprehensive regulatory ability on the periocular microenvironment is limited. Patent CN119745715A provides a composition comprising a novel compound from carnosine or caffeine; it emphasizes its ability to reduce the levels of inflammatory factors IL-6 and TNF-α, providing a soothing effect and addressing facial inflammation in sensitive individuals. However, the preparation and performance of this novel compound have not undergone rigorous verification. In addition, patent CN113693962A discloses a multi-protein repair composition containing fibronectin, which contains more than ten kinds of plant extracts and fermentation products. Although it claims to repair in multiple dimensions, it has defects such as complicated raw materials, difficulty in quality control, high cost, high risk of allergy, and unclear synergistic mechanism. Moreover, it is not specifically designed for periorbital problems.

[0004] Currently, commercially available eye care products commonly use ingredients such as caffeine, vitamin K, and horse chestnut extract. Caffeine can promote circulation and reduce edema, but its mechanism of action is relatively simple, mainly limited to short-term swelling reduction and astringency, with limited effects on inflammation regulation and long-term microvascular stability improvement.

[0005] In summary, the existing technology still has the following shortcomings: 1. Single mechanism of action: Most only target blood circulation or reduce swelling, lacking synergistic regulation of oxidative stress, micro-inflammation and capillary stability.

[0006] 2. Insufficient sustainability of improvement: Some circulation-promoting ingredients only provide immediate reduction in swelling or temporary improvement, making it difficult to alleviate circulation-related dark circles and fatigue-related eye area problems in the long term.

[0007] 3. Lack of innovation in plant-based compound systems: Common technologies mostly focus on the combination of caffeine and traditional active ingredients, while compound systems based on natural ingredients such as Gastrodia elata extract, which also have the effects of promoting microcirculation, anti-oxidation and anti-inflammatory soothing, are relatively rare.

[0008] Therefore, developing a compound eye care composition that combines the effects of promoting microcirculation, anti-oxidation, and anti-inflammation has important application value. Summary of the Invention

[0009] In order to develop a compound eye care composition that combines the effects of promoting microcirculation, anti-oxidation and anti-inflammation, the present invention provides an eye care composition for improving microcirculation around the eyes and its application.

[0010] The objective of this invention can be achieved through the following technical solutions: The present invention provides an eye care composition for improving microcirculation around the eyes, the composition comprising the following components in parts by weight: 0.05-3 parts of Gastrodia elata extract solution, 0.001-0.5 parts of asiaticoside and 0.02-2 parts of Myopurinol 50.

[0011] Miaochunka 50 is a sustained-release system obtained by encapsulating 50% caffeine in cyclodextrin. When used, this sustained-release system can slowly release the active ingredient caffeine onto the skin surface.

[0012] In one embodiment of the present invention, the mass ratio of Gastrodia elata extract solution, asiaticoside, and Myochunka 50 is 1:(0.01-1):(0.5-6), preferably 1:(0.05-0.5):(0.5-4), and more preferably 3:1:2 or 2:1:1.

[0013] In one embodiment of the present invention, the gastrodia extract solution is a solution formed by dissolving gastrodia extract in water, butylene glycol, and 1,2-hexanediol, wherein the mass contents of gastrodia extract, water, butylene glycol, and 1,2-hexanediol in the gastrodia extract solution are 1-3%, 45-50%, 45-55%, and 0.5-2%, respectively.

[0014] Gastrodia elata extract solution, hydroxyascorbic acid, and Miaochunka 50 work synergistically to improve dullness, puffiness, and fatigue of the skin around the eyes by promoting microcirculation of blood around the eyes, soothing inflammation, and reducing oxidative stress, and enhance the radiance and firmness of the skin around the eyes.

[0015] The present invention also provides the use of the eye care composition for improving periocular microcirculation in the preparation of eye care products.

[0016] The present invention also provides an eye care product for improving microcirculation around the eyes, wherein the mass content of Gastrodia elata extract solution is 0.05%-3%, the mass content of hydroxyascorbic acid is 0.001%-0.5%, the mass content of Miaochunka 50 is 0.02%-2%, and the other components are matrix excipients.

[0017] In the aforementioned eye care product, the mass content of Miaochun Coffee 50 is 0.02%-2%, which is equivalent to a mass content of 0.01%~1% caffeine.

[0018] In one embodiment of the present invention, in the eye care product, the total mass content of Gastrodia elata extract solution, asiaticoside, and Myochunka 50 is 0.05% to 5%, more preferably 0.1% to 4%, and the other components are matrix excipients.

[0019] In one embodiment of the present invention, the eye care product is an eye cream, eye serum, eye mask, eye oil, or eye care oil.

[0020] In one embodiment of the present invention, the matrix excipient is selected from one or more of thickeners, humectants, preservatives, emulsifiers, and emollients. The thickener may be selected from one or more of carbomer, xanthan gum, hydroxyethyl cellulose, cetearyl alcohol, PVM / MA copolymer, and polyacrylamide. The humectant may be selected from one or more of glycerin, propylene glycol, butylene glycol, sodium hyaluronate, 1,2-hexanediol, and trehalose. The preservative may be selected from one or more of phenoxyethanol, p-hydroxyacetophenone, methylparaben, and DMDM ​​hydantoin. The emulsifier may be selected from one or more of PEG-40 hydrogenated castor oil, glyceryl stearate, cetearyl alcohol, PEG-100 stearate, and triethanolamine. The emollient may be selected from one or more of petrolatum, squalane, jojoba seed oil, shea butter, macadamia seed oil, ethylhexyl palmitate, and C13-14 isoparaffins.

[0021] This invention utilizes a solution of Gastrodia elata extract as the main component, combined with asiaticoside and Miaochunka 50, to obtain an eye care composition for improving microcirculation around the eyes. This invention constructs a multi-mechanism synergistic system that promotes microcirculation, provides antioxidant effects, and has anti-inflammatory and soothing properties. Specifically, the Gastrodia elata extract solution has nerve-soothing and antioxidant effects; asiaticoside can soothe and calm the skin, repair skin damage, and promote skin regeneration, while also possessing antioxidant and antibacterial properties; Miaochunka 50 promotes local blood circulation and reduces edema. The synergistic effect of these three components can improve dark circles, periorbital dullness, and puffiness caused by microcirculatory disorders, oxidative damage, and inflammatory responses.

[0022] Compared with the prior art, the present invention has the following advantages: This invention applies a solution of Gastrodia elata extract to an eye care composition that improves microcirculation around the eyes. It is scientifically combined with asiaticoside and Miaochunka 50 to form a synergistic system with multiple effects including circulation promotion, anti-oxidation, and anti-inflammatory repair. Existing eye care products often rely on caffeine-based ingredients to simply improve puffiness or alleviate eye area conditions through moisturizing, lacking a systematic approach to addressing the combined effects of microcirculation disorders, oxidative stress, and inflammation leading to dark circles and dullness around the eyes. In this invention, the Gastrodia elata extract solution exerts nerve-soothing and antioxidant effects, reducing the damage of oxidative stress to the microenvironment around the eyes; asiaticoside further exerts anti-inflammatory repair and skin regeneration effects, enhancing skin barrier stability; and Miaochunka 50 promotes local blood circulation and lymphatic metabolism, reducing puffiness around the eyes. The synergistic effect of these three ingredients not only increases nitric oxide levels and improves local microcirculation around the eyes but also simultaneously alleviates inflammatory stimulation and free radical damage, achieving comprehensive regulation of the microenvironment around the eyes. Compared to single-function products, this composition has better sustainability, stability and comprehensive care effects in improving dark circles, dark circles and puffiness, demonstrating significant technological innovation and application value.

[0023] The research results show that the composition provided by the present invention has better comprehensive efficacy than single components, and exhibits a significant synergistic effect. It can not only quickly improve the skin tone around the eyes, but also has a certain degree of sustained effect. It can be used to relieve dark circles, eye bags and eye fatigue caused by poor microcirculation, oxidative stress and inflammatory response.

[0024] This invention combines Gastrodia elata extract solution, asiaticoside, and Miaochunka 50, which not only improves local circulation around the eyes but also comprehensively regulates the microenvironment around the eyes, thereby enhancing the sustainability and stability of the eye care effect. Attached Figure Description

[0025] Appendix Figure 1 This is DPPH clearance rate data.

[0026] Appendix Figure 2 Data on IL-6 levels.

[0027] Appendix Figure 3 This is data on NO content.

[0028] Appendix Figure 4 The EI data for the skin around the eyes after using the eye cream in the combination group in Table 6.

[0029] Appendix Figure 5 The data for ITA° color around the eyes after using the eye cream in the combination group in Table 6. Detailed Implementation

[0030] The present invention will now be described in detail with reference to the accompanying drawings and specific embodiments.

[0031] In the following embodiments: The Gastrodia elata extract solution was purchased from Hubei Nanbang Biomedical Technology Co., Ltd. The Gastrodia elata extract solution used in the following examples is a solution formed by dissolving Gastrodia elata extract in water, butylene glycol, and 1,2-hexanediol. The mass contents of Gastrodia elata extract, water, butylene glycol, and 1,2-hexanediol in the solution are 1-3%, 45-50%, 45-55%, and 0.5-2%, respectively.

[0032] In the following examples, Madcassoside was purchased from Sepico (Shanghai) Specialty Chemicals Co., Ltd.

[0033] Miaochun Coffee 50 was purchased from Suzhou Nakang Biotechnology Co., Ltd., and its ingredients are 50% caffeine and 50% cyclodextrin.

[0034] Human immortalized epidermal keratinocytes (HaCaT) (purchased from Shangen Biotechnology), human dermal microvascular endothelial cells (HDMEC) (purchased from Shangen Biotechnology). High-glucose DMEM medium was purchased from Gibco; DPPH (100 μM, in 99 wt% ethanol).

[0035] Preparation of different samples in Examples 1-5 and Comparative Examples 1-6 Examples 1-5 provide various samples containing different concentrations of Gastrodia elata extract solution, asiaticoside, and Mycotoxin 50. The samples were prepared using high-glucose DMEM medium to create different concentrations of sample solutions, and the concentrations of the main components in the sample solutions are shown in Table 1.

[0036] Comparative Examples 1 to 6 provided samples containing one or two of the following: Gastrodia elata extract solution, asiaticoside, and Mycophenolate Mofetil 50. The samples were prepared using high-glucose DMEM medium to create sample solutions of different concentrations. The concentrations of the main components in the sample solutions of Comparative Examples 1-6 are shown in Table 1. The concentrations of the main components in the samples of Examples 1-5 and Comparative Examples 1-6 are also shown in Table 1.

[0037] Table 1. Concentrations of major components in samples from Examples 1-5 and Comparative Examples 1-6 Gastrodia elata extract solution 0.3% 0.15% 0.15% 0.06% 0.6% 2.5% 1.5% 1% Hydroxyasiaticoside 0.3% 0.15% 0.15% 0.005% 0.05% 0.5% 0.5% 0.5% Miao Chun Ka 50 0.3% 0.15% 0.15% 0.235% 1% 1% 1% 0.5% physiological saline 0.3% Experiment 1 (In the data below, * indicates a significant difference from the control group, P < 0.05; ** indicates a highly significant difference from the control group, P < 0.01.) Cell viability assay (used to verify safety in all groups) HaCaT cells were cultured in control and experimental group samples for 24 hours. The effect of the samples on cell viability was detected by the MTT assay to assess whether the experiment was conducted without affecting cell viability.

[0038] The detailed steps are as follows: 1. Cell Seeding: Cells in the logarithmic growth phase were cultured in high-glucose DMEM medium containing 10% FBS. When the cell density reached approximately 80%, the cells were digested with 0.05% trypsin-EDTA solution and collected by centrifugation at 1000 rpm for 5 minutes. After centrifugation, the cells were resuspended in high-glucose DMEM medium containing 10% FBS and counted using a hemocytometer. The cells were seeded at an appropriate density in 96-well cell culture plates and incubated at 37°C in a 5% CO2 incubator to ensure proper cell adhesion and growth.

[0039] 2. Sample preparation: Sample solutions of different concentrations were prepared using high-glucose DMEM medium containing 10% FBS (the concentrations of the main components in the sample solutions are shown in Table 1). 24 hours after cell seeding, the medium was removed. The NC group was prepared with high-glucose DMEM medium containing 10% FBS. Sample groups (the example and comparative groups in Table 1) were prepared with different concentrations of sample solutions and incubated at 37°C in a 5% CO2 incubator for 24 hours.

[0040] 3. Cellular reaction assay: After 24 hours of sample treatment, the solutions from each group were aspirated, and the cells were gently washed twice with 1×DPBS in each well. Then, 0.5 mg / mL MTT working solution was added to each well, and the cells were incubated in a 37°C, 5% CO2 incubator in the dark for 3 hours. After incubation, the MTT solution was discarded, and DMSO was added to each well to dissolve the generated formazan crystals. The DMSO solution was used as a blank. The absorbance (optical density, OD value) of each well was measured at 550 nm using a microplate reader.

[0041] 4. Data Analysis: By comparing with the NC group, the relative cell viability (%) after treatment with different concentrations of samples was calculated. The data was processed using GraphPadPrism plotting software, and the results are expressed as Mean±SD.

[0042] Relative cell activity (%) = (OD value of sample group - OD value of blank group) / (OD value of NC group - OD value of blank group) * 100%; if relative cell activity (%) < 80%, the sample is determined to have potential cytotoxicity at the test concentration.

[0043] The cell activity of different embodiments, comparative examples, and blank groups is shown in Table 2.

[0044] Table 2 Cell viability data

[0045] Cell viability assays showed that cell viability was greater than 80% after treatment with either the control group or the example, indicating that the tested concentrations had no potential cytotoxicity. Based on these results, subsequent tests can proceed normally.

[0046] Experimental Example 2 Antioxidant test Antioxidant performance was evaluated by testing the DPPH scavenging rate. Each sample underwent a DPPH free radical scavenging experiment to compare the antioxidant capacity of samples from different embodiments and comparative examples. The specific method was as follows: Each sample in Table 1 (1 mL of the supernatant after centrifugation) was mixed with 1 mL of DPPH solution (0.2 mM, 99 wt% ethanol) and incubated in the dark for 60 min. The absorbance of the mixed solution at 517 nm was then measured using a UV-Vis spectrophotometer (1 mL of deionized water was used instead of the sample, and treated with an equal volume of DPPH solution as a control group).

[0047] The following equation was used to calculate: DPPH clearance rate % = (absorbance of control group - absorbance of each example or comparative group) / absorbance of control group × 100%.

[0048] The DPPH scavenging rates of different embodiments and comparative examples are shown in Table 3. Figure 1 As shown.

[0049] Table 3 DPPH removal rate data

[0050] Experimental results show that the Gastrodia elata extract solution has a good DPPH free radical scavenging ability, indicating that it has a certain antioxidant activity. Hydroxyasiaticoside also shows a certain free radical scavenging effect. When used alone, the antioxidant capacity of Miaochunka 50 is relatively weak. When the three are combined, the DPPH free radical scavenging rate is significantly increased. In particular, Examples 2-5 show a significantly enhanced antioxidant effect, indicating that there is a synergistic antioxidant effect among the three.

[0051] Experimental Example 3 Measurement of interleukin-6 (IL-6) 1. Seed HaCaT cells at an appropriate density in 24-well cell culture plates and incubate them in a constant temperature incubator at 37°C and 5% CO2 to ensure normal cell adhesion and growth.

[0052] 2. Sample preparation: The sample group was first stimulated with LPS (1 μg / mL) for 12 h, and then the sample solutions of the example and comparative examples were added respectively. The samples were then incubated in a constant temperature incubator at 37℃ and 5% CO2 for 24 hours.

[0053] 3. Cellular Reaction Assay: After 24 hours of sample treatment, the culture medium was collected and centrifuged at 300g for 10 minutes. IL-6 secretion was detected using an ELISA kit, and a standard curve was established using standards of known concentrations. The OD value of each well was measured at 450nm using a microplate reader. The OD value of each well was converted to IL-6 concentration using the standard curve to assess IL-6 secretion. The data are recorded in Table 4, and the comparative proportions of IL-6 content are shown in Table 4. Figure 2 middle.

[0054] 4. In Table 4, the rate of change of IL-6 = (experimental group - model group) / model group × 100% Table 4 Interleukin-6 Data

[0055] The experimental results showed that the IL-6 level in the model group increased significantly after LPS stimulation, indicating that the inflammation model was successfully established.

[0056] Table 4 shows that the IL-6 change rates are all negative, indicating that individual Asparagus cochinchinensis extract solution, asiaticoside, and Mycophenolate Mofetil 50 can all inhibit IL-6 release to varying degrees, with asiaticoside showing a more significant inhibition rate. The IL-6 inhibition ability of the paired combinations is further enhanced compared to the single-component combinations, indicating a certain synergistic effect between the different components. The ternary compound composition in the embodiments of this invention exhibits a more significant IL-6 inhibition effect.

[0057] Elevated levels of the inflammatory factor IL-6 can lead to abnormal local capillary function and microcirculatory disturbances, further exacerbating dark circles and periorbital discoloration. The composition of this invention, by inhibiting the release of inflammatory factors such as IL-6, can reduce inflammatory damage and improve local microcirculation.

[0058] Test Example 4 Blood circulation enhancement test Experimental objective: To verify the ability of the composition to promote NO release from vascular endothelial cells (HDMECs) using human skin microvascular endothelial cells. Increased NO release indicates that it can promote skin microcirculation, thereby improving dark circles under the eyes.

[0059] Experimental groups: The experimental groups are as shown in Table 1.

[0060] Experimental method: according to 1×10 5Cells were seeded at a density of cells / well into 24-well plates and incubated overnight in an incubator (37°C, 5% CO2). Different concentrations of the test substance working solution (using serum-free high-glucose DMEM medium as the solvent) were prepared according to the experimental groups. When the cell layer coverage in the 24-well plates reached 40%–60%, 100 μL of sample was added to each well, with 3 replicates per group. After administration, the plates were incubated for another 24 h at 37°C, 5% CO2. After incubation, the cell culture supernatant was collected into EP tubes. The collected samples were then frozen at -80°C and analyzed according to the NO kit instructions. The NO content of each experimental group is shown in Table 5. Figure 3 As shown.

[0061] Table 5 NO content data

[0062] Compared with the blank group: the NO level in the Gastrodia elata extract solution group increased by 16.1%; the hydroxyasiaticoside group increased by 7.7%; and the Miaochunka 50 group increased by 25.7%. The synergistic promoting effect of the two was enhanced, and the synergistic effect of the three was more significant: the low-dose group (Example 1) increased by 30.9%; the medium-dose group (Example 2) increased by 54.4%; and the high-dose group (Example 3) increased by 68.8%.

[0063] Since oxidative stress and inflammation can lead to impaired vascular endothelial function and decreased NO bioavailability, the composition of this invention reduces oxidative damage and improves inflammation levels by enhancing free radical scavenging ability, while also improving NO stability, thereby improving local microcirculation and helping to improve dark circles under the eyes.

[0064] Experimental Example 5 Eye periorbital skin hemoglobin index (EI) and ITA° test Experimental participants: 30 people aged 25-45 with obvious dark circles under their eyes were selected and divided into 3 groups of 10 people each.

[0065] Experimental Methods: After cleansing and toning their face in the morning and evening, subjects applied an appropriate amount of eye cream to the eye area according to their experimental groups (see Table 6). The cream was spread evenly and massaged until absorbed. The Erythema Index (EI) of the eye area was measured using an MX18 heme analyzer, and the ITA° of the eye area was measured using a CL400 skin color analyzer, respectively, before use (Day 0), after 4 weeks of use (Day 28), and after 4 weeks of discontinuation (Day 56). The Erythema Index (EI) is a parameter that characterizes the relative content of hemoglobin in the blood vessels of the skin surface by measuring the absorption of a specific wavelength of light on the skin surface. A decrease in the EI value indicates a reduction in hemoglobin retention in the capillary network around the eyes, reflecting an improvement in microcirculation and a reduction in blood stasis within the blood vessels. The Individual Type Angle (ITA°) is calculated from three values ​​in the color system: L*, a*, and b*. ITA° is a numerical value characterizing skin color; the higher the ITA°, the whiter the skin.

[0066] Table 6 Experimental Grouping for Validating Dark Circle Effect

[0067] The eye cream base in Table 6 consists of 0.5-2% thickener, 0.1-10% moisturizer, 0.8-1.5% preservative, 1-8% emulsifier, 15-25% emollient, and the remainder is water.

[0068] Experimental results: The experimental results are shown in Tables 7 and 8. Figure 4 , Figure 5 .

[0069] Table 7. Results of Hemoglobin Index (EI) for the skin around the eyes.

[0070] Table 8 Results of ITA° around the eyes

[0071] Table 7 shows that after 4 weeks of continuous use of the eye cream, both the single control group and the compound group showed a decreasing trend in the EI (erythema index) of the skin around the eyes, with the compound group showing a more significant decrease. Even after 28 days of discontinuation, the EI value of the compound group still showed a 10.3% decrease. Table 8 shows that after 4 weeks of continuous use of the eye cream, both the single control group and the compound group showed an increasing trend in the ITA° (indices of skin tone around the eyes), with the compound group showing a more significant increase. Even after 28 days of discontinuation, the ITA° value of the compound group still showed a 16.1% increase compared to the initial value.

[0072] The results in Tables 7 and 8 show that 28 days after discontinuation of the eye cream, the compound group remained effective in reducing the EI value of the hemoglobin index and improving the ITA° of the skin around the eyes, maintaining the effect significantly better than the single control group. This indicates that the composition of the present invention has a sustained effect on improving the condition of the skin around the eyes. It is speculated that the mechanism is related to the synergistic effect between Gastrodia elata extract solution, asiaticoside, and Miaochunka 50. The three can work together to promote local blood circulation, reduce the level of inflammatory factors and alleviate oxidative stress, reduce blood stasis in blood vessels, and reduce pigment deposition, making the skin around the eyes brighter, thereby continuously improving the microenvironment of the skin around the eyes and the condition of dark circles.

[0073] The above description of the embodiments is provided to enable those skilled in the art to understand and use the invention. It will be apparent to those skilled in the art that various modifications can be made to these embodiments, and the general principles described herein can be applied to other embodiments without inventive effort. Therefore, the present invention is not limited to the above embodiments, and any improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the invention should be within the protection scope of the present invention.

Claims

1. An eye care composition for improving periocular microcirculation, characterized in that, The composition comprises the following components in parts by weight: 0.05-3 parts of Gastrodia elata extract solution, 0.001-0.5 parts of asiaticoside and 0.02-2 parts of Miaochunka 50.

2. The eye care composition for improving periocular microcirculation according to claim 1, characterized in that, The mass ratio of Gastrodia elata extract solution, hydroxyascorbic acid, and Miaochunka 50 is 1:(0.01~1):(0.5~6).

3. The eye care composition for improving periocular microcirculation according to claim 2, characterized in that, The mass ratio of Gastrodia elata extract solution, hydroxyascorbic acid, and Miaochunka 50 is 1:(0.05~0.5):(0.5~4).

4. An eye care composition for improving periocular microcirculation according to claim 3, characterized in that, The mass ratio of Gastrodia elata extract solution, hydroxyascorbic acid, and Miaochunka 50 is 3:1:2 or 2:1:

1.

5. An eye care composition for improving periocular microcirculation according to any one of claims 1-4, characterized in that, The Gastrodia elata extract solution is a solution formed by dissolving Gastrodia elata extract in water, butylene glycol, and 1,2-hexanediol. In the Gastrodia elata extract solution, the mass contents of Gastrodia elata extract, water, butylene glycol, and 1,2-hexanediol are 1-3%, 45-50%, 45-55%, and 0.5-2%, respectively.

6. The use of the eye care composition for improving periocular microcirculation as described in any one of claims 1-4 in the preparation of an eye care product.

7. An eye care product for improving microcirculation around the eyes, characterized in that, In the eye care product, the mass content of Gastrodia elata extract solution is 0.05%-3%, the mass content of hydroxyascorbic acid is 0.001%-0.5%, the mass content of Miaochunka 50 is 0.02%-2%, and the other ingredients are matrix excipients.

8. An eye care product for improving periocular microcirculation according to claim 7, characterized in that, In the eye care product, the total mass content of Gastrodia elata extract solution, hydroxyascorbic acid, and Miaochunka 50 is 0.05% to 5%, and the other ingredients are matrix excipients.

9. An eye care product for improving periocular microcirculation according to claim 8, characterized in that, In the eye care product, the total mass content of Gastrodia elata extract solution, hydroxyascorbic acid, and Miaochunka 50 is 0.1% to 4%, and the other ingredients are matrix excipients.

10. An eye care product for improving periocular microcirculation according to claim 7, characterized in that, The eye care products mentioned are eye creams, eye serums, eye masks, eye oils, or eye care oils.

Images